Document:

Exhibit
10.6

 

AMENDMENT
TO REVOLVING LOAN AND SECURITY AGREEMENT

 

This
Amendment (the “Amendment”) to the Revolving Loan and Security Agreement dated April 28, 2011, as amended on July
26, 2014 and October 31, 2017 (the “Agreement”) is entered into this 31st day of October 2020, by and between Vaxstar
LLC, a Delaware limited liability company (“Vaxstar”), and ValueSetters, Inc. (“ValueSetters”), a Utah corporation,
with reference to the following:

 

READINGS/RECITALS

 

A.    
     The Agreement contains a maturity date of October 31, 2020, and ValueSetters and Vaxstar
desire to extend the maturity date to a time in the future.

 

B.     
     Both parties seek to amend the Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing, of the mutual promises hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Paragraph
9 (k) of the Agreement is amended to read:

“Maturity
Date” means January 31, 2021.

 

Paragraph
1. (d) (i) of the Agreement is amended to read:

Subject
to Section 7(b)(ii), the principal amount outstanding under the Loan Advances shall accrue interest from the date of this Amendment
until the Maturity Date at the rate of eight percent (8%) per annum, compounding daily. Interest is not due until the Maturity
Date.

 

COUNTERPARTS:
This Amendment may be executed simultaneously in one or more counterparts, each of which when executed and delivered shall be
deemed an original, but all of which together shall constitute a single agreement.

 

IN
WITNESS WHEREOF, the parties hereto have entered into this Amendment as of the date written above.

 

	Vaxstar LLC 	 
	 	 	 
	Signature:		 
	 	Cecilia
    Lenk, Manager	 
	 	 	 
	ValueSetters, Inc	 
	 	 	 
	Signature:		 
	 	Coreen
    Kraysler, CFOExhibit 10.7

 

AMENDMENT
TO REVOLVING LOAN AND SECURITY AGREEMENT

 

This
Amendment (the “Amendment”) to the Revolving Loan and Security Agreement dated April 28, 2011, as amended on July
26, 2014 and October 31, 2017 (the “Agreement”) is entered into this 31st day of January 2021, by and between Vaxstar
LLC, a Delaware limited liability company (“Vaxstar”), and Netcapital Inc. (“Netcapital”), a Utah corporation,
with reference to the following:

 

READINGS/RECITALS

 

A.            The Agreement, as amended, contains a maturity date of January 31, 2021, and Netcapital
and Vaxstar desire to extend the maturity date to a time in the future.

 

B.            Both parties seek to amend the Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing, of the mutual promises hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Paragraph
9 (k) of the Agreement is amended to read:

“Maturity
Date” means April 30, 2021.

 

Paragraph
1. (d) (i) of the Agreement is amended to read:

Subject
to Section 7(b)(ii), the principal amount outstanding under the Loan Advances shall accrue interest from the date of this Amendment
until the Maturity Date at the rate of eight percent (8%) per annum, compounding daily. Interest is not due until the Maturity
Date.

 

COUNTERPARTS:
This Amendment may be executed simultaneously in one or more counterparts, each of which when executed and delivered shall be
deemed an original, but all of which together shall constitute a single agreement.

 

IN
WITNESS WHEREOF, the parties hereto have entered into this Amendment as of the date written above.

 

	Vaxstar LLC	 
	 	 
	Signature:		 
	 	Manuel Teixeira, Manager	 

 

	ValueSetters, Inc	 
	 	 
	Signature:		 
	 	Coreen Kraysler, CFOExhibit 10.8

 

AMENDMENT TO REVOLVING LOAN AND SECURITY
AGREEMENT

 

This Amendment (the
“Amendment”) to the Revolving Loan and Security Agreement dated April 28, 2011, as amended on July 26, 2014 and October
31, 2017 (the “Agreement”) is entered into this 31st day of January 2021, by and between Vaxstar LLC, a Delaware limited
liability company (“Vaxstar”), and Netcapital Inc. (“Netcapital”), a Utah corporation, with reference to the
following:

 

READINGS/RECITALS

 

A.      The
Agreement, as amended, contains a maturity date of April 30, 2021, and Netcapital and Vaxstar desire to extend the maturity date
to a time in the future.

 

B.       Both
parties seek to amend the Agreement.

 

NOW, THEREFORE, in
consideration of the foregoing, of the mutual promises hereinafter set forth and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Paragraph 9 (k) of the Agreement is amended
to read: 

“Maturity Date” means April
30, 2022.

 

COUNTERPARTS: This Amendment may be executed
simultaneously in one or more counterparts, each of which when executed and delivered shall be deemed an original, but all of which
together shall constitute a single agreement.

 

IN WITNESS WHEREOF, the parties hereto
have entered into this Amendment as of the date written above.

 

	Vaxstar LLC	 
	 	 	 
	Signature:		 
	 	Manuek Teixeira, Manager	 
	 	 	 
	ValueSetters, Inc	 
	 	 	 
	Signature:		 
	 	Cecilia Lenk, CEOEXHIBIT 10.1

 

THIRD AMENDMENT TO

EMPLOYMENT AGREEMENT

 

This Third Amendment to Employment
Agreement (this “Amendment”) is executed on this seventh day of April 2022, and made effective as defined below
(the “Effective Date”), by and between Christopher Missling, PhD (hereinafter referred to as
“Executive”) and Anavex Life Sciences Corp. (“Employer” and, together with its subsidiaries,
the “Company”) and serves to amend that certain Employment Agreement dated June 27, 2013, as amended from time
to time (the “Employment Agreement”), by and between Executive and the Company. Except as otherwise provided
in this Amendment, capitalized terms used in this Amendment shall have the same meanings given to them in the Employment Agreement. Executive
and Company are collectively referred to as the “Parties” and singularly referred to as “Party.”

 

RECITALS

 

WHEREAS, Executive currently
is employed by the Company pursuant to the terms of the Employment Agreement; and

 

WHEREAS, the Parties desire
to amend the Employment Agreement as described below, but to otherwise maintain in effect in full all other terms of the Employment Agreement.

 

NOW, THEREFORE, for good
and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties agree as follows:

 

AMENDMENT

 

		1.	ADOPTION OF RECITALS. The Parties adopt the above recitals as being true and correct, and
they are incorporated herein as material parts of this Amendment.

 

		2.	SECTION 1. The Parties agree that Section 1 of the Employment Agreement shall be amended
and restated as follows:

 

		1.	Term. The term of your employment hereunder shall commence on July 5th, 2022 (the “Start
Date”) and shall end on the earliest of (i) July 5th, 2025, (ii) the date on which your employment is terminated by Company
or you pursuant to Paragraph 10 or (iii) the date of your death or the date of termination of your employment by reason of incapacity
(determined in accordance with Paragraph 8) (the “Employment Term”). The period from the Start Date until July 5th,
2025, regardless of any earlier termination, shall hereinafter be referred to as the “Original Employment Term”.

 

		3.	SECTION 3. The Parties agree that Section 3 of the Employment Agreement shall be amended
and restated as follows:

 

		3.	Cash Compensation.

 

		(a)	Base Salary. In consideration for the services performed by you pursuant to this Agreement, the
Company shall pay to you, and you will be entitled to receive and hereby agree to accept, an initial annual base salary of $700,000, subject
to increases in the discretion of the Board or its Compensation Committee (“Base Salary”), payable in accordance with
the Company’s normal payroll payment practices.

 

     

     

    

 

The Compensation Committee of the Board
(the “Compensation Committee”) may review your salary at least annually and may increase (but not decrease) the Base
Salary. The result of any such review shall be reported to you by the Compensation Committee promptly after it occurs.

 

		(b)	Annual Bonus Compensation. In addition to your Base Salary, during the Employment Term you shall
be eligible to earn an annual cash bonus for each whole or partial calendar year during the Employment Term, (the “Bonus”)
of up to $140,000. Commencing July 5th, 2022, your target bonus for each calendar year during the Employment Term shall be twenty percent
(20%) of annualized Base Salary, as in effect on July 5th, 2022 of each applicable performance year; provided that the Compensation Committee
may review your target bonus at least annually and may increase (but not decrease, including as it may be increased from time to time)
the target bonus. The result of any such annual review shall be reported to you by the Compensation Committee promptly after it occurs.
Your target bonus, as it may be so increased from time to time, is referred to herein as the “Target Bonus”. As the
actual amount payable to you as Bonus will be dependent upon the achievement of certain performance goals, your actual Bonus may be less
than, greater than or equal to the Target Bonus. Your actual Bonus shall be determined by the Board of Directors, with suggestions from
the Compensation Committee, at the end of each whole year during the Employment Term.

 

		(c)	Your Bonus for each whole calendar year during the Employment Term, beginning with 2022, will be based
upon achievement of performance goals established by the Compensation Committee, which may include individualized performance goals applicable
uniquely to you. The Company shall deliver to you a list of that year’s performance goals by end of 1st quarter of each year.

 

		4.	SECTION 4. The Parties agree that Section 4 of the Employment Agreement shall be amended
and restated as follows:

 

4. Stock
Options. In addition to your Base Salary and Bonus, you shall receive the following stock option grants:

 

		(i)	You shall be entitled to 500,000 options for shares of the Company’s Common Stock which shall be
granted upon the filing of an S-8 Registration Statement for the 2022 Equity Incentive Plan. The options shall vest one third each upon
the

 

		●	Completion of ANAVEX2-73-AD-004 Phase 2b/3 study in Alzheimer’s disease

 

		●	Initiation of ANAVEX2-73 imaging-focused Parkinson’s disease clinical trial

 

		●	Initiation of ANAVEX2-73 Phase 2/3 Fragile X clinical trial

 

Each such option shall have an exercise
price equal to the closing price of the Common Stock on the grant date.

 

Upon a Change in Control, all previously
granted but unvested stock options shall vest.

 

[Signature page follows.]

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement
on April 7, 2022.

 

	COMPANY:	 	EXECUTIVE:
	ANAVEX LIFE SCIENCES CORP.	 	CHRISTOPHER MISSLING, PHD
	 	 	 	 	 
	By:	/s/ Sandra Boenisch	 	By:	/s/ Christopher Missling
	Name: 	Sandra Boenisch	 	 	 
	Title: 	Principal Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]